Half Title Page.
Table of Contents.
1: Catecholamine Biosynthesis and Storage.
2: Genetic Manipulation of Catecholamine Signaling in the Mouse.
3: AADC Deficiency: Occurring in Humans; Modeled in Rodents; Treated in Patients.
4: Tyrosine Hydrolylase and Dopamine Beta-Hydroxylase: Role of Common Genetic Variation in Adrenergic Responses to Stress and in Hypertension.
5: Pharmacokinetic and Pharmacodynamic Properties of Etamicastat, a New DBH Inhibitor: Comparison to Nepicastat.
6: Estradiol-Mediated Regulation of Gene Expression of Catecholamine Biosynthetic Enzymes: The Role of Membrane-Initiated Signaling with Erα.
7: Structural Basis for Regulation of Tyrosine Hydroxlyase by the Catecholamines.
8: Unique Regulation of TH Gene Expression in Midbrain Dopamine Neurons.
9: Intracellular Stability of Tyrosine Hydroxylase: Phosphorylation and Proteasomal Digestion of the Enzyme.
10: The Peripheral Interaction of Tyrosine Hydroxylase and 14-3-3γ with Negatively Charged Phospholipidic Membranes.
11: Dynamic Regulation of Tyrosine Hydroxylase Gene Expression by Key Fate-Determining Transcription Factors during Dopaminergic Neuronal Development in Vivo and in Vitro.
12: Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease.
13: Non-dopaminergic Neurons Partly Expressing Dopaminergic Phenotype: Functional Significance and Regulation.
14: Developing Brain as an Endocrine Organ: Catecholamines Secretion and Endocrine Action.
15: Brainstem DOPAergic System.
16: Imaging Norepinephrine Transporters in Humans; Translational Research with PET.
17: Imaging the Vesicular Monoamine Transporter (VMAT2) in Neurodegenerative Diseases.
18: GTP Cyclohydrolase Regulation: Implications for Brain Development and Function.
19: Neonatal Diagnosis of Menkes Disease by a Pattern of Plasma Catechols.
20: Catecholamine Metabolites Affected by the Copper-Dependent Enzyme Dopamine-Beta-Hydroxylase Provide Sensitive Blood and Csf Biomarkers for Viral Gene Therapy in Menkes Disease.
21: Are the Enzymes of the Catecholamine Biosynthetic Pathway Locally Synthesized in the Axon?.
22: Effects of Missense Mutations in Tyrosine Hydroxylase (TH) Found in Patients with Neurological Disorders Attributed to TH Deficiency.
23: Tetrahydrobiopterin Deficiency Impairs Postnatal Increase of TH Protein via Insufficient Dopamine Biosynthesis.
24: Selective Ablation of Dopamine Beta-Hydroxylase Neurons (Subpopulation of TH Neurons) in the Brain: New Insights into Brain Catecholaminergic Circuitry and Catecholamine-Related Diseases.
25: Neural Circuit Mechanism for Learning Dependent on Dopamine Transmission: Roles of Striatal Direct and Indirect Pathways in Sensory Discrimination.
26: Regulation of Tyrosine Hydroxylase by Ser19-Phosphorylation-Dependent Binding to 14-3-3γ.
27: Modeling the Dynamics of Dopamine Biosynthesis and its Regulation by Tyrosine Hydroxylase.
28: Reassessment of Intrinsic Dopaminergic Innervation in the Human Enteric Nervous System – Clinical Implications.
29: Midbrain Dopamine Neurons are Divided into Different Functional Groups.
30: Cell-, Region- and Species-Specific Expression of VMAT2: Implications for Medical Imaging With High-Affinity Transporter Ligands.
31: Catecholamine Release and Re-uptake.
32: Detecting Catecholamines – A Journey from Beaker to the Behaving Brain.
33: Functional Disturbances in DA Homeostasis and Signaling Revealed Through the Study of Rare Dopamine Transporter Coding Variants.
34: Norepinephrine Transporter A457P Knockin Mice Display Tachycardia and Anxiety-Like Behavior.
35: In Vivo Mutations in the Trafficking Domain of the Drosophila Vesicular Monoamine Transporter Disrupt Specific Amine-Dependent Behaviors.
36: Fate of the Chromaffin Granule Membrane and its Protein Constituents after Fusion.
37: Catestatin (Human Chromogranin A352-372) Induces Lipolysis and Fatty Acid Oxidation through Regulation of Adrenergic and Leptin Signaling.
38: Introduction: From Mystery Matrix Proteins to Precise Molecular Actions in Human Disease.
39: A New Take on Uptake: Dopamine Transporters & the Cellular Mechanisms of Amphetamine Action.
40: A Retrospective on PET and the Amphetamine Paradigm: Validation and Paradoxes.
41: The Corelease of Glutamate by Dopamine Neurons.
42: Psychostimulant-Induced Alterations of Monoaminergic Transporters: Implications for Neurotoxicity and Neuroprotection.
43: Trace Amine Associated Receptor 1 is a Catecholamine Receptor that Differentially Controls DAT and NET Internalization.
44: VGF-Derived Peptide TLQP-21: Structure, Function, and Biomedical Implications.
45: Chromogranins the Key Proteins for the Storage and Regulation of Exocytosis in Chromaffin Cells.
46: Chromogranin A in the Storage and Exocytosis of Catecholamines.
47: The Involvement of Vesicular ATP in the Storage and Exocytosis of Catecholamines of Bovine Chromaffin Cells.
48: The Role of Ca2+ Release from the Endoplasmic Reticulum in the Catecholamine Hypersecretion of Adrenal Chromaffin Cells from Spontaneously Hypertensive Rats.
49: PACAP as a Primary Effector of the Acute Sympatho-Adrenal Stress Response.
50: Amphetamine Induced Dopamine Release in Macaque Monkeys: Striking Differences Between Prefrontal Cortex and Caudate Nucleus.
51: Attenuated Amphetamine-Induced Dopamine Release in Subjects at Ultra-High Risk for Substance Dependence.
52: The Membrane-Raft Protein Flotillin-1 is Essential in Dopamine Neurons for Amphetamine-Induced Behavior in Drosophila.
53: Plant Flavonoids Affecting Adrenal Medullary Catecholamine Biosynthesis and Release.
54: A Protein Complex for Dopamine Synthesis and Vesicular Storage: Target for Cellular Oxidative Damage.
55: Overexpression of Parkin in The Nigrostriatal System Might Protect Dopaminergic Terminals From Methamphetamine Neurotoxicity Via Regulation of Dopamine Transporter.
56: Increased Catecholamine Toxicity in Mice with Low Expression of VMAT2.
58: Renalase: A New Player in Catecholamine Metabolism.
59: Abnormal Monoamine Oxidase A VT in the Prefrontal and Anterior Cingulate Cortex During Major Depressive Episodes and High Risk States for Major Depressive Episodes.
60: CNS Catecholamine Metabolism – Emerging Concepts.
61: Catestatin (Human Chromogranin A352-372) Induces Lipolysis and Fatty Acid Oxidation through Regulation of Adrenergic and Leptin Signaling.
62: Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models.
63: Understanding Catecholamine Metabolism as a Guide for Assessment of Sympathoadrenal Function and Dysfunction in Health and Disease.
64: Multiplex Immunoassay for Catecholamines.
65: Modifiers of Neurofibromatosis-Associated Tumors and the Potential Role for Catecholamines and Sex Differences.
66: Catecholamine Metabolism in Chromogranins Knock-Out Mice.
67: Translation Research in Autism and Cancer: Novel Roles of MAO.
68: COMT is a Major Contributor to Pain Perception: from Humans to Rats and Back to Humans.
69: Novel COMT Inhibitors in Parkinson Disease.
70: Effect of Opicapone, a New Catechol-O-Methyltransferase Inhibitor, in Levodopa Pharmakokinetics in the Cynomolgous Monkey.
71: Does Impaired Aldehyde Detoxification Play a Role in Parkinson's Disease?.
72: The Role of Aldehyde Detoxification in Parkinson's Disease.
73: Pharmacological Profile of Opicapone in Wistar rat.
74: Catecholamine Receptors and Catecholaminergic Signaling.
75: How Drugs Bind and Control their Targets: Characterizing GPCR Signaling through Long-Timescale Simulation.
76: Structural basis of Subtype Selectivity in Dopamine D3 and D2 Receptors.
77: Hormone-Mediated Activation of G Proteins by GPCRs: Insights from the Crystal Structure of a GPCR-G Protein Complex.
78: Towards Better Understanding of G(s) Coupling in Catecholamine Receptors.
79: Receptor Heteromerization: Understanding the Functional and Pathological Role of the Dopamine D4 Receptor.
80: Trace Amines and Their Receptors: New Opportunities for Modulation of Brain Dopaminergic Functions.
81: Cross-Talk between G Protein-Coupled Receptors: Challenges of Distinguishing Upstream from Downstream Mechanisms.
82: Growth Hormone Secretagogue Receptor (GHSR1a, aka Ghrelin Receptor) is an Allosteric Modulator of Dopamine Signaling in the Brain via Formation of GHSR1a:DRD2 and GHSR1a:DRD1 Heteromers.
83: Regulation of β2Adrenergic Receptor Trafficking and Signaling by Ubiquitination and Deubiquitination.
84: Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling.
85: Trafficking of the D2 Dopamine Receptor Promotes Drug-Induced Changes in Neuronal and Behavioral Plasticity.
86: D2 Receptors Control of Dopamine Levels.
87: Integrated Approaches to Understand the Actions of GPCRs: The b-Arrestin-Dependent D2R Mediated Signaling Through Akt/GSK3.
88: Hyperdopaminergic Modulation of Inhibitory Transmission is Dependent on GSK-3β Signaling-Mediated Trafficking of GABAA Receptors.
89: Simultaneous, Massively Parallel and Genome-Wide Interrogation of GPCR b-arrestin-ergic Signaling: Implications for GPCR Drug Discovery and Catecholamine Biology.
90: Backwards and Forwards with Molecular and Classical Pharmacology.
91: Targeting Beta-Arrestin Dependent Signaling in the Treatment of Parkinson's Disease.
92: D2 Functionally Selective Ligands: novel Therapeutics?.
93: Investigation of the D1-D2 heteromer: pharmacology, subunit composition, and mechanisms of signaling.
94: β-Adrenergic Receptors, Caveolae and Caveolins: Receptor Localization and Function.
95: Protein Kinase C β and the Dopamine Transporter Influence Surface D2-Like Dopamine Receptor Localization.
96: Role of Adrenaline on the Maturation of β2-Adrenoceptors.
97: Deciphering the Functionally Selective Properties of D2R Ligands.
98: Chronic loss of Noradrenergic Tone Produces β-Arrestin2-Mediated Cocaine Hypersensitivity and a GαI to Gαs switch in D2 Receptor Coupling in the Nucleus Accumbens.
99: Probing the Functional Selectivity of β-adrenergic Receptors Reveals New Signaling Modes and Potential Therapeutic Applications.
100: Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor.
101: Novel cAMP Sensor Links GPCR-Gs Signaling to ERK in Neuroscreen-1 Cells.
102: High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes.
103: Discovery and Characterization of TAAR1 Agonists, Modulators of Dopaminergic and Serotonergic Neurotransmission with Therapeutic Potential in Neuropsychiatric Disorders.
105: Modeling Parkinson's Disease in a Mouse Model Overexpressing Astrocytic Monoamine Oxidase B (MAO-B): Towards Exploring Novel Therapeutics.
106: 3,4-Dihydroxyphenylacetaldehyde is an Autotoxic and Protein-Reactive Intermediate of Dopamine Catabolism.
107: Dopamine Oxidation and Quinone Modification of Proteins: Mechanisms of Toxicity and Implications for Parkinson's Disease.
108: Insights into LRRK2-Mutation Related PD from PET Imaging Studies.
109: Norepinephrine Deficiency in Parkinson Disease.
110: Progressive Noradrenergic Degeneration in Mice with Reduced Expression of the Vesicular Monoamine Transporter (VMAT2).
111: LRRK2 and Risk of PD.
112: Synuclein-Mitochondrial Interactions in Substantia Nigra Dopamine Neurons.
113: Mitochondria-Targeted Cholesterol Oximes Increase Dopamine-Related Gene Expression and Behavior in Mice Over-Expressing Alpha-Synuclein, a Model of Pre-Manifest Parkinson's Disease.
114: Induction of Chaperone-Mediated Autophagy as a Means to Attenuate Alpha-Synuclein-Mediated Neurotoxicity.
115: The Link between Neuronal Phenotype and Vulnerability in Parkinson's Disease.
116: Willie Sutton's Getaway Car and the Pathogenesis of Parkinson Disease.
117: Contributions of Dopamine in the Dorsal Striatum to Behaviors Corresponding to Cognitive Dysfunction in Parkinson's Disease.
118: Cardiac Sympathetic Denervation: A Biomarker of Lewy Body Diseases.
119: Cerebrospinal Fluid Biomarkers of Central Catecholamine Deficiency in Parkinson Disease and Other Synucleinopathies.
120: Comparison Between Myocardial Sympathetic and Striatal Dopaminergic Imaging in Lewy Body Diseases: “Union is strength!”.
121: A Role For Neuronal MHC-I Display in Parkinson's Disease?.
122: Modeling of Preclinical and Clinical Stages of Parkinsonism in MPTP-treated Mice with Focus on Tyrosine Hydroxylase in Survived Nigrostriatal Dopaminergic Neurons.
123: Role of Multiple Factors in Susceptibility of Neurons in Parkinson's Disease.
124: Modeling of Presymptomatic and Symptomatic Stages of Parkinsonism in MPTP-treated Mice: Extra-nigrostriatal Manifestations.
125: Basal and Graded 6-OHDA –induced Differences in Striatal Dopamine and its Metabolites in two Mouse Lines with A30P–Mutated Alpha-Synuclein.
126: Rasagiline Reduces Striatal Dopamine Release and Extracellular Oxidative Stress in a Rat Model of Early Parkinson's Disease.
127: Approach Towards Development of Multifunctional Drugs As an Effective Strategy for Treatment of Parkinson's Disease.
128: Triple Deuteration Modifies Pharmacokinetics and Pharmacodynamics of Dopamine in PD Models.
129: Psychiatry and Psychology.
130: Rewarding Dopamine.
131: Modulating Local Circuit Dynamics versus Long-Range Inputs.
132: Midbrain Dopamine Neurons are Divided into Different Functional Groups.
133: Dopamine System Dysregulation by the Hippocampus and the Pathophysiology of Schizophrenia.
134: The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia: In Vivo Evidence from the Prodrome to the First Psychotic Episode.
135: Striatal Dopamine Release in Schizophrenia Comorbis with Substance Dependence.
136: Neuroimaging Studies of Central Catecholaminergic Function in Depression.
137: Central and Peripheral Norepinephrine Secretion in Major Depression is Activated, as Assessed by 24 hour CSF and Plasma Sampling.
138: Norepinephrine: A Broken Spoke on the Wheel of Depression.
139: PET Imaging of Serotonin Transmission in Monkeys: Effects of Maternal Separation and Long-Term Fluoxetine Treatment during Adolescence.
140: Opposing Regulation of Norepinephrine and Dopamine in Rat Limbic Brain Regions in Response to Aversive Stimuli.
141: The Locus Coeruleus, Stress, Opioids and Behavioral Flexibility.
142: Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis.
143: Evaluation of [11C]ORM-13070 as a PET tracer for α2C-adrenoceptors in the human brain.
144: Drug Abuse and Addiction.
145: Addiction: Story of an Unbalanced Brain.
146: Essential Catecholamine Influences on Dorsolateral Prefrontal Cortical Cognitive Function: Molecular Signaling Pathways.
147: Neural Mechanisms Underlying the Cognition-Enhancing Actions of Pyschostimulants: Relevance to ADHD.
148: Frontostriatal Systems and Differential Roles of Dopamine D1- and D2-Like Receptors in Impulsivity and Response Inhibition.
149: Catecholamine Strategies for Remediating Fronto-Executive Deficits in Stimulant Addiction and Related Disorders.
150: Ultrastructural and Optogenetic Evidence for Dual Neuronal Signaling by Dopamine Neurons of the Ventral Tegmental Area (VTA).
151: Seeking reward: Upstream modulation of VTA dopamine neurons by orexin/hypocretin inputs.
152: Striatal Dopamine, Self-control and Decision-Making: Identifying Therapeutic Targets for Addiction through Brain Imaging.
153: Imaging Neurochemical Transmission in Substance Abuse: Commonalities and Differences Across Addictions.
154: Dopamine Transmission in Cocaine Addiction: Linking the Animal and Human Studies.
155: Growth Associated Protein-43, Amphetamine and Dopamine Transporter Activity.
156: The Role of Ion Binding in Transporter Conformational Transition.
157: Evidence for the Contribution of D4 Receptors to Cocaine Self-Administration in Monkeys.
158: Drug Design for Addiction – Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor.
159: Cue-Induced Dopamine Release in Striatal and Extra-striatal Regions in Cocaine Dependent Users: A High Resolution PET [18F]Fallypride Study.
160: β-arrestin Regulation of Ghrelin Signaling in modulating Addictive Behavior.
161: Dopamine D3 and D4 Receptors as Therapeutic Targets for Nicotine Addiction.
162: Long-Term Cocaine Exposure Affects Dopamine D3 Receptor Function.
163: Catecholamines in the Periphery.
164: Recurrent Hypoglycemic Stress Differentially Regulates Catecholamine Release and Transmitter Gene Expression.
165: Sympathetic Mechanism of Hypertension.
166: Harnessing the Autonomic System for Therapeutic Intervention.
167: Norepinephrine Transporter Function and Human Cardiovascular Regulation.
168: Role of Common Genetic Variation in Control of Human Adrenergic Function and Blood Pressure: Focus on the Chromogranins.
169: What is the Optimal Biochemical Diagnostic Strategy for Pheochromocytoma?.
170: SDHx-Related Pheochromocytoms: New Advances in Genetics and Functional Imaging.
171: Novel Methods Peripheral Autonomic Assessment.
172: Identification and Functional Characterization of Genetic Variants of the Catecholamine Release-Inhibitory Peptide Catestatin in an Indian Population.
173: The Osmopressor Response in Human Physiology.
174: Adrenergic Derived Myocardium: Anatomic Substrate for Stress Induced Cardiomyopathies.
175: The Relationship of Norepinephrine to Stress Induced Hypertension.
176: Regulation of Adrenal Phenylethanolamine N-methyltransferase Gene Expression and Adrenaline Synthesis in a Fetal Programming Model of Hypertension.
177: Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland.
178: Effect of Daidzein on Mean Arterial Pressure and Vascular Dysfunction in CLP-Induced Septic Mice.
179: Adrenal-Specific G Protein-Coupled Receptor Kinase (GRK)-2 Deficiency Reduces Circulating Catecholamine Levels and Improves Cardiac Function after Myocardial Infarction.
180: Serotonin and Catecholamines In Regulation of Myocardium Functions in Children with Congenital Heart Diseases.
181: “Genetic and Acquired Determinants of Postural Tachycardia Syndrome”.
182: Neurotransmitter dopamine regulates tumor growth.
183: Extra Virgin Olive Oil Increases Uncoupling Protein 1 Content in Brown Adipose Tissue and Enhances Noradrenaline and Adrenaline Secretions in Rats.
184: Neurovisceral Integration and Regulation of Peripheral Indices of ANS Function.
185: Catecholamines in Integrative Function.
186: Neuropeptide Y Infusion to Rats Attenuates Development of PTSD-Like Symptoms to Traumatic Stress.
187: PTSD and the Locus Coeeurleus.
188: Systems Biology and the Stress Response: From Pythagoras and the Epicureans to Modern Medicine.
189: Reactive Oxygen Species and Neuropeptide Y Signaling in Altered Catecholamine Synthesis during Intermittent Hypoxia.
190: Stress, HIF1a, and Adrenergic Function.
191: Characterization of Cerebrospinal Fluid (CSF) and Plasma NPY Levels in Normal Volunteers over a 24-h Timeframe.
192: NPY: Low Cerebrospinal Fluid (CSF) Levels in Posttraumatic Stress Disorder in Comparison to Combat and Civilian, non-combat Control Subjects.
193: Developmental Neuroendocrinology of Posttraumatic Stress Disorder in Children and Adolescents after Motor Vehicle Accidents.
194: Repeated and Novel Stress-triggered Changes in Adipocyte Catecholamine System.